gastric juice comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
==== Ligand exchange ==== Post-synthetic modification techniques can be used to exchange an existing organic linking group in a prefabricated MOF with a new linker by ligand exchange or partial ligand exchange. This exchange allows for the pores and, in some cases the overall framework of MOFs, to be tailored for specific purposes. Some of these uses include fine-tuning the material for selective adsorption, gas storage, and catalysis. To perform ligand exchange prefabricated MOF crystals are washed with solvent and then soaked in a solution of the new linker. The exchange often requires heat and occurs on the time scale of a few days. Post-synthetic ligand exchange also enables the incorporation of functional groups into MOFs that otherwise would not survive MOF synthesis, due to temperature, pH, or other reaction conditions, or hinder the synthesis itself by competition with donor groups on the loaning ligand.
=== Refugee Lodges of Hispaniola === In 1748, on Cuba's neighboring island of Hispaniola, Freemasonry in Haiti was established by the Grande Loge de France with the St. Jean de Jérusalem Ecossais (English: St. John of Jerusalem) in Cap-Français, Saint-Domingue (known today as Haiti). The second Haitain Lodge was chartered in 1765 at Los Cayos, called Les Frères Réunis No. 1 (English: Reunited Brothers). When the Haitian Revolution started, a mass exodus of French and Saint-Domingue Creole refugee emigres left Saint-Domingue and settled in Cuba. Freemasonry was allowed to continue for some time during the war in Saint-Domingue, where Huet de la Chapelle had become the Grand Master of the French Provincial Grand Loge in 1795, until a change in government forced the Haitian Lodges to flee the island and relocate elsewhere. As that conflict then spilled over the border into Santo Domingo (known today as the Dominican Republic), the Eastern half of that island also experienced a wave of emigration as Spaniards fled the colony. Most of these refugees from Saint-Domingue and Santo Domingo landed in the port towns of Oriente Province, especially Baracoa and Santiago de Cuba. In 1798, La Bénéfique Concorde was reestablished in Baracoa, La Persévérance was reestablished in Santiago de Cuba, and La Concorde L'Amitié relocated to Havana. The charters for these French Lodges, however, specifically limited their activities to Hispaniola.
=== Equipment loan program === Upon the conclusion of the SHIELD Illinois testing program, laboratory equipment and other hard assets were offered to public entities throughout the State of Illinois at no cost with the understanding that, should another pandemic occur, the equipment would be used however necessary to continue the mission of SHIELD Illinois to keep Illinois open.
== External links == A more advanced video detailing the different types of post-translational modifications and their chemical structures A useful video visualising the process of converting DNA to protein via transcription and translation Video visualising the process of protein folding from the non-functional primary structure to a mature, folded 3D protein structure with reference to the role of mutations and protein mis-folding in disease
Since their conceptualization in 1998, several advances have been made in terms of the variety of types of microneedles that can be fabricated. The 5 main types of microneedles are solid, hollow, coated, dissolvable/dissolving, and hydrogel-forming. The distinct characteristic of each type of MNs allow a variety of clinical applications, including diagnosis and treatment. Micro-sized needles in a microneedles (MNs) device can be as short as 25μm or even 2000μm in length depending on their types.
Sources: en.wikipedia.org
=== Pharmacokinetics === There are small differences in the pharmacokinetics between different sublingual buprenorphine/naloxone products. These differences may require changes in dose when a person switches from one product to another. The buprenorphine/naloxone sublingual film (e.g. trade name Suboxone) achieves higher buprenorphine maximum plasma concentrations (Cmax) and area under the curve (AUC, a measure of total drug exposure) than the original buprenorphine/naloxone sublingual tablets at equal doses. For example, at a buprenorphine/naloxone dose of 8 mg/2 mg, the buprenorphine Cmax after a single dose of the original tablet formulation is around 3 ng/mL whereas that of the 8 mg/2 mg film formulation is around 3.55 ng/mL. The Zubsolv trade name sublingual tablets have higher buprenorphine bioavailability than the original sublingual tablets, while the Bunavail trade name buccal films have the highest bioavailability. For example, a single dose of Bunavail 4.2 mg/0.7 mg achieves a Cmax around 3.41 ng/mL.
BRD-6929 is a selective inhibitor of HDAC1 and HDAC2, with IC50Tooltip half-maximal inhibitory concentration values of 1 nM and 8–30 nM, respectively, and with 30- to 400-fold selectivity over HDAC3 (IC50 = 398–458 nM) and no inhibition of HDAC8 or class II HDACs (IC50 = >30,000 nM). However, although originally reported to be selective for inhibition of HDAC1 and HDAC2 over HDAC3, subsequent research has found that BRD-6929 is not in fact selective over HDAC3, with previous findings being claimed to have been an assay artifact. As a result, BRD-6929 is no longer recommended as a selective HDAC1 and HDAC2 inhibitor. The drug shows slow-on/slow-off binding kinetics and hence more sustained HDAC inhibition, unlike other HDAC inhibitors like the fast-on/fast-off vorinostat (SAHA) and entinostat (MS-275). Aside from the HDACs, it also showed no binding at 80 other targets at a concentration of 10,000 nM. BRD-6929 produces antidepressant-like and mood-stabilizing-like effects in rodents. This included reducing immobility in the forced swim test (FST) and attenuating amphetamine-induced hyperlocomotion without affecting basal locomotor activity. Conversely, vorinostat was ineffective in these tests. In addition, vorinostat showed dissimilar and lesser effects on gene transcription compared to BRD-6929. These differences may be related to selectivity and duration of exposure, with sustained exposure as with BRD-6929 possibly being advantageous.
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue. There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms. The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered. The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis. Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease. Treatment is with thyroid hormone replacement. Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.
Chromosome 3 open reading frame 62 (C3orf62) is a protein that in humans is encoded by the C3orf62 gene. C3orf62 is a glycine-depleted protein relative to the amount of glycine in proteins in the rest of the genome. C3orf62 has a KKXX-like motif and is predicted to be localized in the nucleus. Expression of C3orf62 remains highest in whole blood.
Gearbox Software was founded on February 16, 1999, by Randy Pitchford, Brian Martel, Stephen Bahl, Landon Montgomery and Rob Heironimus, five developers formerly of Rebel Boat Rocker. Before Rebel Boat Rocker, Pitchford and Martel previously worked together at 3D Realms, and Montgomery previously worked at Bethesda Softworks. By 2000, the company employed 15 people. They started with developing expansions to Valve's Half-Life. Porting Half-Life to console platforms (each with new game content) followed, building the company's experience in console game-making, in addition to enhancing and building upon the successful Counter-Strike branch of the Half-Life franchise. Prior to Half-Life 2, it had developed or helped develop every Half-Life expansion game or port, including Opposing Force, Blue Shift, Counter-Strike: Condition Zero, Half-Life for the Sony PlayStation 2 (including Half-Life: Decay), and Half-Life for the Sega Dreamcast (including Blue Shift). Branching out to other publishers, it pursued additional port work, each game being released with additional content, but this time from console to PC. These projects included its first non-first-person shooter, Tony Hawk's Pro Skater 3, and Halo: Combat Evolved, forging new publisher relationships with Activision and Microsoft Game Studios respectively. Additional new development, in the form of a PC game in the James Bond franchise (James Bond 007: Nightfire) for Electronic Arts, also occurred during the company's initial 5-year period.
Sources: en.wikipedia.org
Synthetic organisms may offer increased hazard control because they can be engineered with "intrinsic" biocontainment methods that limit their growth in an uncontained environment, or prevent horizontal gene transfer to natural organisms. Examples of intrinsic biocontainment include auxotrophy, biological kill switches, inability of the organism to replicate or to pass modified or synthetic genes to offspring, and the use of xenobiological organisms using alternative biochemistry, for example using artificial xeno nucleic acids (XNA) instead of DNA.
=== Misuse for chemical reaction === The term sublimation refers specifically to a physical change of state and is not used to describe the transformation of a solid to a gas in a chemical reaction. For example, the dissociation on heating of solid ammonium chloride into hydrogen chloride and ammonia is not sublimation but a chemical reaction. Similarly the combustion of candles, containing paraffin wax, to carbon dioxide and water vapor is not sublimation but a chemical reaction with oxygen.
=== 2000-present === In 2000, the company opened a central laboratory in Singapore, building on clinical-development services formed in Singapore in 1996. In 2013, it expanded the capacity of the laboratory by 50%. In March 2001, the company sold Covance Pharmaceutical Packaging Services to Fisher Scientific for $137.5 million. In August 2005, it acquired GFI Clinical Services, an 80-bed clinical pharmacology business, from West Pharmaceutical Services for $5.7 million. In April 2006, the company acquired eight early phase clinical pharmacology sites from Radiant Research for $65 million. In June 2006, it acquired Signet Laboratories, a provider of monoclonal antibodies used in the research of cancer, infectious disease, and neurodegenerative disease, for $8.95 million. In 2007, the company opened a laboratory in Shanghai, China. In 2019, it opened a research and development center in Shanghai. In August 2008, the company acquired a campus in Greenfield, Indiana from Eli Lilly and Company and executed a 10-year service drug development service agreement with Lilly. In December 2008, the company acquired a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry. The company was acquired by Chicago Growth Partners in July 2012. In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services.
However, CSP expressing secretions and tissues are not only the female moth pheromone gland, but also antennal branches, mandibles and salivae, cephalic capsula, eyes, proboscis, thorax and abdomen, head, epidermis, fat body, gut, wings and legs, i.e. a wide range of reproductive and non reproductive, sensory and non-sensory fluids and tissues of the insect body [28-31]. Nearly all CSPs are up regulated in most of all tissues from the insect body, particularly in the gut, epidermis and fat body, following insecticide exposure [32].
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy 2V, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to a deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to break down glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and the nervous system. GSD-II and Danon disease are the only glycogen storage diseases characterised by a defect in lysosomal metabolism. It was first identified in 1932 by Dutch pathologist Joannes Cassianus Pompe, making it the first glycogen storage disease to be discovered.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.